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Abstract
The aim of this treatment study was to evaluate the therapeutic eﬀects of repetitive transcranial magnetic
stimulation (rTMS) over the right parietal cortex in depression. In a double-blind, sham-controlled design
ten consecutive sessions of 2 Hz rTMS (inter-pulse interval 0.5 s) at 90% motor threshold to the right
parietal cortex (2400 pulses per session) were applied to 34 patients with the primary diagnosis of DSM-IV
depression and a score ofo15 on the 17-itemHamilton Rating Scale for Depression (HAMD). The primary
outcome measures were the percentage change from baseline on the 17-item HAMD scores after ten
sessions, and the percentage of clinical (deﬁned aso50% reduction in HAMD score) and partial clinical
(deﬁned as o30% reduction in HAMD score) responders. Reduction of HAMD scores in the real rTMS
treatment (meanreal¡S.D., x19.9¡32.5%) was not statistically diﬀerent from the sham rTMS treatment
(meansham¡S.D.,x5.6¡28.4%), and the number of clinical responders did not diﬀer between treatments.
However, a signiﬁcant greater number of partial clinical responders were observed in the real (43.8%)
compared to the sham rTMS treatment (6.3%). This study provides the ﬁrst evidence showing that 2 Hz
rTMS over the right parietal cortex may have antidepressant properties, and warrants further research.
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Introduction
Ever since the ﬁrst positive eﬀects on mood were
observed in two depressed patients after undergoing
repetitive transcranial magnetic stimulation (rTMS)
over the prefrontal cortex (PFC), rTMS has been ex-
plored as a safe and non-invasive method to treat
clinical depression (Hoﬂich et al., 1993). Earlier ﬁnd-
ings showing tonic reductions in left anterior activity
in depression (Baxter et al., 1989) inspired researchers
to apply fast frequency (o10 Hz) rTMS to increase left
PFC activity (e.g. Avery et al., 2006 ; George et al.,
1997 ; Koerselman et al., 2004). A recent meta-analysis
examining 30 double-blind, sham controlled rTMS
treatment studies performed over the past 20 yr,
showed that fast-frequency repetitive rTMS over the
left PFC is superior to sham rTMS but is only moder-
ately eﬀective in treating non-psychotic depression
(Schutter, 2008). Although the antidepressant eﬃcacy
of rTMS is comparable to several commercially avail-
able pharmacological agents (Kirsch et al., 2008), sev-
eral suggestions have been made to further improve
the eﬀectiveness of rTMS. These include, among oth-
ers, prolongation of treatment duration, intensiﬁcation
of stimulation parameters, and consideration of brain
regions other than the PFC (Herrmann and Ebmeier,
2006 ; Loo and Mitchell, 2005 ; Schutter and van Honk,
2005). Indeed, diﬀerent treatment durations and
stimulation parameters have been investigated (e.g.
Fitzgerald et al., 2003 ; O’Reardon et al., 2007). Despite
the fact that meta-analytical studies show that rTMS
applied to DLPFC has antidepressant properties, they
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remain inconclusive concerning clinical eﬃcacy.
Several methodological strategies have been proposed
to improve the eﬃcacy of DLPFC rTMS which among
others includes using higher stimulation intensities,
prolonged treatment duration and increased stimulus
frequency (Loo and Mitchell, 2005). However, struc-
tural, functional and chemical abnormalities asso-
ciated with depression are not limited to the DLPFC
exclusively (Ressler and Mayberg, 2007). The explo-
ration of the antidepressant eﬀects of rTMS to brain
regions other than the DLPFC may therefore also be
worthwhile (Schutter and van Honk, 2005). The
stimulation of alternative brain regions may identify
other cortical areas importantly involved in the patho-
physiology of depression and might perhaps contrib-
ute knowledge to future rTMS treatment studies. To
the best of our knowledge, no clinical studies have as
yet addressed other cortical brain regions for rTMS in
the treatment of depression.
Lesion and neuroimaging studies in humans sug-
gest that the parietal cortex could be a candidate
alternative cortical region (e.g. Heller and Nitschke,
1998 ; Mayberg et al., 1999 ; Starkstein et al., 1989;
Uytdenhoef et al., 1983). One line of evidence suggests
that reduced activity, in particular of the right pos-
terior parietal cortex, reﬂects reduced autonomic
arousal and responsiveness in depression (Heller,
1993 ; Henriques and Davidson, 1997). In contrast, in-
creased right parietal cortex activity has also been ob-
served in depressed patients. It has been proposed
that the role of the parietal cortex in depression is
mediated by anxiety (Keller et al., 2000) ; a mental state
characterized by increased autonomic arousal and
heightened levels of attention wherein the parietal
cortex is importantly involved (Heller, 1993).
Moreover, right posterior lesions have been shown
to augment exploratory and approach-related behav-
iour in rats, whereas increased right-to-left parietal
resting-state activity positively correlates to more
approach-related attentional processing in non-
depressed volunteers (Crowne et al., 1987; Schutter
et al., 2001). Recently, in a single-blind counter-
balanced rTMS experiment we explored the relation-
ship between the right parietal cortex and emotional
processing in healthy volunteers. Eﬀects on mood,
autonomic activity and motivated attention were in-
vestigated by comparing a single session of 20 min real
rTMS [2 Hz, 90% motor threshold (MT), 2400 pulses]
over the right parietal cortex to a single session of
20 min sham rTMS (2 Hz, 90% MT, 2400 pulses, coil
tilted 90x). Results showed signiﬁcant reductions in
depressive mood in the real compared to sham rTMS,
immediately following stimulation as well as after 30
min. Mood changes were accompanied by autonomic-
mediated and emotional responses to angry facial
expressions, indicative of enhanced approach-related
motivation (van Honk et al., 2003). These data in
healthy volunteers provide the ﬁrst evidence for a
modulatory eﬀect of rTMS to the right parietal cortex
in the regulation of phenomenological, physiological
and attentional aspects of depressive functioning. In
sum, these ﬁndings prompted us to conduct a double-
blind, sham-controlled study to evaluate the possible
antidepressant eﬀects of ten consecutive sessions of
right parietal cortex rTMS with similar parameters
as the study above in a sample of patients with the
primary diagnosis of DSM-IV depression.
Method
Patients
Thirty-four in-patients and outpatients with the pri-
mary diagnosis of depressive disorder according to
DSM-IV-TR criteria (APA, 2000) and a score ofo15 on
the Hamilton Rating Scale for Depression (HAMD)
were enrolled in the intention-to-treat study between
July 2004 and December 2007. Current depressive
disorder was conﬁrmed by the Structured Clinical
Interview for DSM-IV, Research Version (SCID-I ; First
et al., 1996). Demographic and clinical characteristics
of the patients are given in Table 1.
Exclusion criteria were history of seizures, neuro-
logical conditions, metal objects in or around the body
that cannot be removed (i.e. cochlear implant, surgical
clips, piercing, cardiac pacemaker), heart disease,
pregnancy, drug and alcohol abuse. Patients taking
psychotropic medication were accepted on the
Table 1. Demographic and clinical characteristics
rTMS treatment
characteristics Real (n=17) Sham (n=17) p valuea
Age, mean¡S.D. (yr) 44.4¡11.8 43.8¡12.5 0.88
Female/male (n) 10/7 7/10 0.49
Medication (n) 9 8 0.99
History of ECT (n) 3 1 0.60
Baseline HAMD
(mean¡S.D.)
20.9¡5.0 21.4¡6.1 0.83
Baseline HAMA
(mean¡S.D.)
23.5¡7.4 24.2¡7.1 0.78
Total dropouts 1 1 1.00
ECT, Electroconvulsive therapy; HAMD, Hamilton
Depression Rating Scale ; HAMA, Hamilton Anxiety Rating
Scale.
a Two-tailed.
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condition that antidepressant dosage had been stable
for the last 6 wk and that the dosage of hypnotics had
remained unchanged in the past 2 wk. Dosage and
type of medication were kept constant during the
treatment phase. A complete overview of medication
use is shown in Table 2.
All patients received full written and verbal infor-
mation on the study protocol. Written informed con-
sent was obtained prior to enrolment. The study was
approved by the medical ethical committee of Free
University Medical Center and St Lucas Andreas
Hospital, Amsterdam, and in accordance with the
Declaration of Helsinki.
Study design
In the current double-blind, sham controlled parallel-
group study patients were randomly allocated to
receive either real or sham rTMS treatment on ten con-
secutive working days (i.e. 2 wk) via sealed envelopes
opened immediately before the start of the ﬁrst treat-
ment by the clinician administrating rTMS. Prior to
entering the study the patient underwent standard
clinical, psychiatric and laboratory tests and was
screened for contraindications to rTMS. Baseline de-
pression and anxiety scores were acquired with the
17-item HAMD and the 14-item Hamilton Anxiety
Rating scale (HAMA) to assess the inﬂuence of anxiety
on HAMD outcome. Clinical assessment was repeated
after the ﬁnal treatment session. All ratings and tests
were performed by trained researchers blind to treat-
ment. Finally, upon completion of the trial and after the
ﬁnal ratings patients were debriefed and asked to in-
dicate whether they had received sham or real rTMS.
At the end of the entire study patientswere informed of
their actual treatment. Sham rTMS-treated patients
who were still classiﬁed as depressed after treatment
were oﬀered the opportunity to undergo 2 wk of real
rTMS.
TMS procedure
Transcranial magnetic stimulation was performed
using a high-frequency Magpro Dantec magnetic
stimulator with a MCF-B65 ﬁgure-of-eight coil
(Medtronic, Skovlunde, Denmark). At the start of the
ﬁrst session individualMT of the right hemispherewas
established using the visual twitch method to deter-
mine the ﬁxed stimulation intensity (Pridmore et al.,
1998) ; mean¡S.D. MTreal [88.3¡18.0 dI/dt (A/s)] and
mean¡S.D. MTsham [76.9¡17.5 dI/dt (A/s)]. In the
course of 2 wk patients received ten 20-min sessions of
2 Hz rTMS at 90% MT (i.e. 2400 pulses per session).
Stimulation occurred over the P4 electrode site ac-
cording to the International 10–20 EEG System target-
ing the right parietal cortex (Okamoto et al., 2004). The
coil was held tangentially to the scalp with the handle
pointing to the back and oriented away from the coil’s
midline at 45x. For sham stimulation a specially de-
signed ﬁgure-of-eight coil was used. This coil mimics
the sensation and sound click of real rTMS, but pre-
vents the magnetic ﬁeld from reaching the target tissue
through interception by a built-in permalloy shield
plate (MC-P-B70, Medtronic). Stimulation parameters
and procedure were in accordance with the safety
guidelines as formulated by the International Feder-
ation of Clinical Neurophysiology (http://www.ifcn.
info). Contact between the physician applying rTMS
and patient was kept to a minimum.
Statistical analyses
For the primary outcome measure a general linear
model (GLM) for univariate analyses with rTMS
treatment (real vs. sham) as ﬁxed factor and the per-
centage change from baseline on the HAMD scores as
dependent variable was performed. Baseline HAMA
score, age, medication (yes/no), sex (male/female)
were entered separately as covariates. Fisher’s exact
probability tests were used to compare the number of
clinical (deﬁned as o50% reduction in HAMD score)
and partial clinical (deﬁned as o30% reduction in
HAMD score) responses between real and sham rTMS
treatments (Mosimann et al., 2004). The success of
study blinding was tested with binomial and Fisher’s
exact probability tests. For all tests a signiﬁcance level
of 0.05 (two-tailed) was applied.
Results
Tolerability of rTMS
Thirty-four patients originally entered the study. Two
patients dropped out in the ﬁrst week of treatment.
Table 2. Psychotrophic medication during real and sham
rTMS treatment
MAOI SSRI SNRI NaSSA Neuroleptics Hypnotics
Real 1 4 2 2 3 3
Sham 0 3 4 0 2 3
Total 1 7 6 2 5 6
MAOI, Monoamine oxidase inhibitor ; SSRI, selective
serotonin reuptake inhibitor ; SNRI, serotonin noradrenaline
reuptake inhibitor ; NaSSA, noradrenergic and selective
serotonergic antidepressant ; Hypnotics, classical
antipsychotics.
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One female medication-free patient (aged 50 yr)
originally allocated in the real rTMS treatment con-
dition withdrew from the study due to site pain. The
second dropout was a male olanzapine (10 mg) and
promethazine (100 mg) medicated patient (aged 49 yr)
originally randomized to the sham rTMS treatment
condition who experienced intolerable discomfort. In
the remaining 32 patients rTMS was well tolerated and
no seizures occurred. The most common reported
side-eﬀects were headache and stimulation of the right
facial muscles during the ﬁrst sessions.
Blinding of the study
The percentage correct guesses within the real (5/16)
and sham (9/16) rTMS treatment groups did not diﬀer
from chance (test proportion 0.5) as shown by two
separate binominal tests (both p values >0.4).
Moreover, the real and sham rTMS treatment groups
did not diﬀer in their number of correct guesses
(p<0.29). These ﬁndings demonstrate that blinding of
the study was successful.
Primary outcome measure
The percentage change from baseline on the HAMD
scores in the real rTMS treatment (meanreal¡S.D.,
x19.9¡32.8) was not statistically signiﬁcant from the
sham rTMS treatment [meansham¡S.D., x5.6¡28.4 ;
F(1, 31)=1.75, p=0.20, g2=0.06]. Baseline HAMA
scores, age, medication and sex did not inﬂuence the
lack of a treatment diﬀerence (all p values >0.18). In
Figure 1 the mean¡S.E.M. HAMD decreases for real
and sham rTMS treatments over time are depicted.
Fisher’s exact probability test did not show a dif-
ference between number of clinical responders (de-
ﬁned as o50% reduction in HAMD score) in the real
(3/16) and sham (1/16) rTMS treatments (p=0.60).
However, a signiﬁcant greater number of partial
clinical responders (deﬁned as o30% reduction in
HAMD score) was observed in the real (7/16) com-
pared to sham (1/16) rTMS treatments (p=0.04).
Figure 2 shows the percentage of partial clinical re-
sponses in the real (43.8%) and sham (6.3%) rTMS
treatment groups. The partial clinical responders did
not signiﬁcantly diﬀer from non-responders on base-
line HAMA scores, age, and MT (all p values >0.43).
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Figure 1. (a) Mean¡S.D. Hamilton Rating Scale for Depression (HAMD) scores over time, (b) mean¡S.D. percentage
change from baseline HAMD scores after real and sham rTMS treatments.
0
20
40
60
80
100
Real Sham
%
 P
ar
ti
al
 c
lin
ic
al
 r
es
p
o
n
se
Figure 2. Signiﬁcant larger partial clinical response after
real compared to sham rTMS treatments to the right
parietal cortex.
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Fisher’s exact probability tests did not demonstrate
signiﬁcant medication or sex diﬀerences between
partial-clinical and non-responders (both p values
>0.21).
Discussion
To our knowledge, rTMS treatment studies of de-
pression until now have targeted the PFC exclusively.
This is the ﬁrst treatment study that has evaluated the
antidepressant eﬀects of rTMS to the right parietal
cortex in a double-blind, sham-controlled design.
Despite the absence of a statistical group diﬀerence
of treatment, ten sessions of real rTMS resulted in a
signiﬁcant larger number of partial clinical responders
than sham rTMS treatment. It has been suggested that
such a diﬀerence could, at least partially, be explained
by individual diﬀerences in therapeutic onset in re-
sponse to the intervention, a phenomenon commonly
observed with antidepressant drug agents (Reid
and Stewart, 2001). Regardless of these individual
diﬀerences in onset we found signiﬁcantly more par-
tial clinical responders in the real compared to the
sham rTMS treatment conditions providing the ﬁrst
evidence in support of possible antidepressant proper-
ties of rTMS over the right parietal cortex.
Baseline HAMA scores did not play a role in med-
iating the antidepressant eﬀects in the treatment com-
parison. Neither did the partial clinical responders
diﬀer from non-responders on the HAMA score at
baseline (p=0.43). Even though baseline HAMD
scores positively correlated with HAMA score [r(34)=
0.42, p=0.013], there was insuﬃcient diﬀerentiation of
baseline HAMA scores to evaluate whether right par-
ietal cortex rTMS in depression is more eﬀective in
patients with comorbid anxiety (cf. Schutter and van
Honk, 2005).
Furthermore, even though we failed to identify
signiﬁcant diﬀerences between partial clinical and
non-responders on age, medication and sex, the ob-
servation that ﬁve out of the six partial clinical re-
sponders in the real rTMS treatment conditions were
female is notable and concurs with recent ﬁndings
showing superior antidepressant response rates in fe-
males compared to males (Yang et al., 2007 ; but see
Conca et al., 2000). It has been suggested that steroid
hormone ﬂuctuations during the menstrual cycle may
be involved (Marte´nyi et al., 2001). Abnormal cortical
excitability during the luteal phase has been found in
women with premenstrual syndrome. This phenom-
enon has been interpreted as a result of decreased
GABAergic inhibition to progesterone secretion, as
evidenced by rTMS (Smith et al., 2003).
Concerning the biological basis for antidepressant
eﬀects of rTMS on the right parietal cortex, there is
evidence available indicating that depression can be
associated with a dysfunction of a cortico-cortical
circuit, that comprises the left PFC and the right
parietal cortex (Schutter et al., 2002, 2005; Schutter
and van Honk, 2005). Restoration of the functional
connectivity or balance in brain circuits may underlie
the antidepressant properties of rTMS (Mayberg et al.,
1999). Interestingly, basic neuroscientiﬁc research has
shown increased functional connectivity between the
left prefrontal and right parietal cortex following fast-
frequency rTMS over the left PFC (Jing and Takigawa,
2000). This series of studies coincides with research on
the relation between hypothalamus–pituitary–adrenal
(HPA) axis dysfunction and depression, and with
observations of functional cortico-cortical connectivity
breakdown in depression (Belanoﬀ et al., 2002 ; Cook
et al., 2000 ; Gold et al., 2002). Additional support
comes from vagus nerve stimulation in the treatment
of depression. As measured with positron emission
tomography during electrical stimulation of cranial
nerve X in four patients with treatment-resistant major
depression, Conway and colleagues (2006) found
blood ﬂow to increase in the frontal cortex and to
decrease in the right parietal cortex.
Considering the fact that only 2 wk of stimulation
were used the results appear promising and suggest
that stimulating the right parietal cortex especially
using longer treatment durations may also be ther-
apeutically helpful in depression. Furthermore, as al-
ready noted in the Introduction, depressive disorders
are more likely to be associated with dysfunctional
neural networks rather than abnormalities in a single
brain region. The dense connectivity between parietal
and frontal cortex provides anatomical evidence for
this view. It is suggested that modulating cortico-
cortical networks by, for instance, simultaneously ap-
plying high-frequency rTMS to the left DLPFC and
low-frequency rTMS to the right parietal cortex may
yield synergetic eﬀects. Moreover, in the modulation
of cortico-cortical networks transcranial direct current
stimulation (tDCS) might prove to be a valuable tool in
the success of non-invasive brain stimulation in the
treatment of depression (Boggio et al., 2008). In tDCS a
pair of electrodes is aﬃxed to the head in an anodal-
cathodal montage through which a weak electrical
current is passed. Previous research has shown that
cortical excitability is increased under the anodal
electrode, whereas cortical excitability is decreased
under the cathodal electrode (Nitsche et al., 2007).
Analogues to bilateral rTMS (Fitzgerald et al., 2006),
anodal tDCS to the left DLPFC and cathodal tDCS to
Parietal cortex rTMS treatment of depression 647
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the right parietal cortex could in theory be an eﬀective
way to treat depression. Alternatively, it is feasible
that stimulation over any cortical region can trigger
therapeutic neurobiological responses. This would
mean that rTMS applied to the cortex activates the
aforementioned cortico-cortical networks or subserves
a ‘gateway’ function by activating subcortical moti-
vational brain circuits (Strafella et al., 2001). However,
recent ﬁndings from a tDCS study argues against
this ‘cortical generalizability’ hypothesis by showing
antidepressant eﬀects in response to DLPFC tDCS, but
not following tDCS to the occipital cortex (Boggio et al.,
2008). These results seem to suggest that the cortical
eﬀects of rTMS are conﬁned to association areas and
depend on connections with subcortical brain regions.
Despite the fact that 43.8% of the patients showed a
partial clinical response after real rTMS treatment vs.
6.3% after sham rTMS treatment, the study was ham-
pered by several limiting factors. The fact that the
percentage change in HAMD scores was not signiﬁ-
cantly diﬀerent between real and sham rTMS treat-
ments after ten sessions in 2 wk may indicate that the
sample size as well as the amount of sessions were
insuﬃcient. Several recent large rTMS trials in which it
was shown that real vs. sham rTMS-related anti-
depressant eﬀects start to diﬀer after 2 wk of treatment
in favour of real rTMS (Avery et al., 2006 ; O’Reardon
et al., 2007). These ﬁndings coincide with therapeutic
onset delays frequently found in regular pharmaco-
logical treatments (Anderson et al., 2000 ; but see
Mitchell, 2006). Moreover, as with the present study,
many studies are hampered by improvement in de-
pression symptoms independent of treatment con-
dition in the ﬁrst 2 wk of treatment. Possible reasons
for these improvements include regaining daily life
routines and increased social interactions. Longer
treatment durations may therefore be necessary to
dissociate general improvements from true rTMS-
related antidepressant eﬀects. In sum, we anticipate
greater antidepressant eﬀects to treatment durations
ofo3 wk in future studies targeting the right parietal
cortex.
Although we found reductions in depressive mood
after 2 Hz rTMS to the right parietal cortex in our
previous study (van Honk et al., 2003), the intensity of
the stimulation used in the present study may also
have been too low for clear-cut eﬀects. Indeed, there is
some evidence suggesting that antidepressant re-
sponses positively vary as a function of intensity,
at least with prefrontal cortex rTMS (Herrmann and
Ebmeier, 2006; Padberg et al., 2002). Results from a
meta-analysis on factors that modify the anti-
depressant eﬀects of rTMS demonstrated that the
therapeutic eﬀects, even though remaining signiﬁ-
cantly larger than sham rTMS, fell in studies using
stimulation intensities below 90%MT, (Herrmann and
Ebmeier, 2006). In contrast, no signiﬁcant diﬀerences
in therapeutic eﬃcacy were observed between studies
that used stimulation intensities of<100%MT (n=14)
compared to studies that used stimulation intensities
of >100% MT (n=16, p=0.65) (Schutter, 2008). It re-
mains debatable whether higher intensity rTMS is
more eﬀective, but the fact that scalp-parietal cortex
distance appears larger than scalp-PFC distance
(Knecht et al., 2005) nonetheless suggests that future
studies targeting the parietal cortex in the treatment of
depression might beneﬁt from higher stimulation in-
tensities. Furthermore, Avery and colleagues (2006)
proposed that the use of ﬂexible rather than ﬁxed-dose
designs may yield greater response rates by increasing
the amount of magnetic pulses at higher intensities
and sessions during treatment. Furthermore, anti-
depressant eﬃcacy may be further improved by ex-
clusively selecting a subgroup of depressed patients
with comorbid anxiety for right parietal cortex rTMS
treatment. Finally, the sex diﬀerence in partial clinical
response is notable and suggests that hormonal ﬂuc-
tuations might be a potential biomarker for the eﬃcacy
of rTMS treatment.
In conclusion, in spite of the above noted limitations
this study provides the ﬁrst direct evidence for ben-
eﬁcial eﬀects of rTMS treatment over the right parietal
cortex in the treatment of depression and warrants
further research.
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